Grand Pharma (00512.HK) announced on November 5 that CBT-001 (GPN00153), an investigational eye drop, met the primary endpoint in a multinational, multicenter Phase III trial for pterygium. The company reported efficacy at both doses and statistically significant improvements in redness and lesion size. The findings could support a future marketing application.
CBT-001 is a multikinase inhibitor designed to target fibrovascular growth by blocking pathways involved in angiogenesis and fibrosis. Earlier studies reported sustained reductions in vascular growth and redness, with a favorable safety profile. The article also discusses potential use across disease severities and in preventing postoperative recurrence.
Pterygium can grow from the conjunctiva onto the cornea and impair vision. The article reports that no drug had been approved specifically for the condition and cites a postoperative recurrence range of 31% to 83% and a global prevalence estimate of 10.2%. Frost & Sullivan estimated that the global patient population would rise from over 900 million in 2023 to 1.059 billion in 2033, with around 150 million patients in China. It projected a global drug market of nearly US$1.8 billion by 2033, with a 58.6% compound annual growth rate from 2028 to 2033.
Source: http://finance.eastmoney.com/a/202611053923436593.html